Oral Composition for Inflammatory Disorders via Synergistic Cytokine Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory and immune disorders related to pro-inflammatory cytokines are invasive, costly, and often have significant side effects, limiting their effectiveness for non-life-threatening conditions.
Innovation Solution
A pharmaceutical composition combining methylsulphonylmethane (MSM), glucosamine, and glycine, or their pharmaceutically acceptable salts or derivatives, which targets different aspects of pro-inflammatory cytokine pathways, providing a synergistic effect to treat inflammatory and immune disorders without invasive methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to treat inflammatory disorders, then the therapeutic effect is improved, but the treatment becomes invasive and costly
Solution Approach 1:
The patent replaces expensive, invasive monoclonal antibody treatments with a combination of cheaper, orally administrable compounds (MSM, glucosamine, glycine) that provide sustained therapeutic effect without the need for injection or complex medical intervention
Solution Approach 2:
The patent substitutes the mechanical/invasive method of antibody injection with a chemical/pharmacological approach using orally administered compounds that systemically reduce pro-inflammatory cytokine production through biochemical mechanisms
2Reliability
If monoclonal antibodies are used to treat inflammatory disorders, then the therapeutic effect is improved, but the treatment cost increases significantly
Solution Approach 1:
The patent employs inexpensive compounds (MSM, glucosamine, glycine) that can be manufactured at low cost compared to monoclonal antibodies, making treatment accessible for non-life-threatening conditions while maintaining therapeutic efficacy through synergistic action
Solution Approach 2:
The patent creates a composite therapeutic formulation combining three distinct compounds (MSM, glucosamine, glycine) that work synergistically to inhibit pro-inflammatory cytokine production, achieving therapeutic effects comparable to expensive monoclonal antibodies at a fraction of the cost
3Reliability
If high dosages of MSM are used to reduce inflammatory symptoms, then the therapeutic effect is improved, but the risk of side effects increases
Solution Approach 1:
The patent combines three compounds (MSM, glucosamine, glycine) in specific ratios where each component contributes to the anti-inflammatory effect through different mechanisms, allowing lower individual dosages to achieve the same therapeutic effect as high dosages of a single compound, thereby reducing side effects
Solution Approach 2:
The patent changes the dosage parameters by distributing the therapeutic load across three compounds rather than relying on a single high-dose compound, with each compound administered at lower, safer levels while maintaining overall therapeutic efficacy through their combined action
Data Source
AI summary
The invention relates to the treatment of an inflammatory or immune disorder with a pharmaceutical composition including methylsulphonylmethane, glucosamine and glycine or pharmaceutically acceptable salts or derivatives of these compounds.